152 related articles for article (PubMed ID: 21239831)
1. Renal insufficiency and failure.
Dimopoulos MA; Terpos E
Hematology Am Soc Hematol Educ Program; 2010; 2010():431-6. PubMed ID: 21239831
[TBL] [Abstract][Full Text] [Related]
2. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
Dimopoulos MA; Terpos E; Chanan-Khan A; Leung N; Ludwig H; Jagannath S; Niesvizky R; Giralt S; Fermand JP; Bladé J; Comenzo RL; Sezer O; Palumbo A; Harousseau JL; Richardson PG; Barlogie B; Anderson KC; Sonneveld P; Tosi P; Cavo M; Rajkumar SV; Durie BG; San Miguel J
J Clin Oncol; 2010 Nov; 28(33):4976-84. PubMed ID: 20956629
[TBL] [Abstract][Full Text] [Related]
3. [Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
Renal Impairment of Multiple Myeloma Collaborative Study Group
Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):871-875. PubMed ID: 29136724
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Dimopoulos MA; Christoulas D; Roussou M; Kastritis E; Migkou M; Gavriatopoulou M; Matsouka C; Mparmparoussi D; Psimenou E; Grapsa I; Efstathiou E; Terpos E
Eur J Haematol; 2010 Jul; 85(1):1-5. PubMed ID: 20192988
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Bridoux F; Chen N; Moreau S; Arnulf B; Moumas E; Abraham J; Desport E; Jaccard A; Fermand JP
Cancer Chemother Pharmacol; 2016 Jul; 78(1):173-82. PubMed ID: 27286995
[TBL] [Abstract][Full Text] [Related]
6. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
7. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.
Dimopoulos MA; Sonneveld P; Leung N; Merlini G; Ludwig H; Kastritis E; Goldschmidt H; Joshua D; Orlowski RZ; Powles R; Vesole DH; Garderet L; Einsele H; Palumbo A; Cavo M; Richardson PG; Moreau P; San Miguel J; Rajkumar SV; Durie BG; Terpos E
J Clin Oncol; 2016 May; 34(13):1544-57. PubMed ID: 26976420
[TBL] [Abstract][Full Text] [Related]
8. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis and treatment of renal failure in multiple myeloma.
Dimopoulos MA; Kastritis E; Rosinol L; Bladé J; Ludwig H
Leukemia; 2008 Aug; 22(8):1485-93. PubMed ID: 18528426
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
João C; Freitas J; Gomes F; Geraldes C; Coelho I; Neves M; Lúcio P; Esteves S; Esteves GV
Ann Hematol; 2016 May; 95(6):931-6. PubMed ID: 27068406
[TBL] [Abstract][Full Text] [Related]
12. Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.
Khan R; Apewokin S; Grazziutti M; Yaccoby S; Epstein J; van Rhee F; Rosenthal A; Waheed S; Usmani S; Atrash S; Kumar S; Hoering A; Crowley J; Shaughnessy JD; Barlogie B
Leukemia; 2015 May; 29(5):1195-201. PubMed ID: 25640885
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H
Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112
[TBL] [Abstract][Full Text] [Related]
15. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.
Parikh GC; Amjad AI; Saliba RM; Kazmi SM; Khan ZU; Lahoti A; Hosing C; Mendoza F; Qureshi SR; Weber DM; Wang M; Popat U; Alousi AM; Champlin RE; Giralt SA; Qazilbash MH
Biol Blood Marrow Transplant; 2009 Jul; 15(7):812-6. PubMed ID: 19539212
[TBL] [Abstract][Full Text] [Related]
16. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
Bladé J; Sonneveld P; San Miguel JF; Sutherland HJ; Hajek R; Nagler A; Spencer A; Robak T; Cibeira MT; Zhuang SH; Harousseau JL; Orlowski RZ;
Clin Lymphoma Myeloma; 2008 Dec; 8(6):352-5. PubMed ID: 19064400
[TBL] [Abstract][Full Text] [Related]
17. Renal function in older hospital patients is more accurately estimated using the Cockcroft-Gault formula than the modification diet in renal disease formula.
Péquignot R; Belmin J; Chauvelier S; Gaubert JY; Konrat C; Duron E; Hanon O
J Am Geriatr Soc; 2009 Sep; 57(9):1638-43. PubMed ID: 19682124
[TBL] [Abstract][Full Text] [Related]
18. The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?
Terpos E; Christoulas D; Kastritis E; Katodritou E; Pouli A; Michalis E; Papassotiriou I; Dimopoulos MA;
Eur J Haematol; 2013 Oct; 91(4):347-55. PubMed ID: 23829647
[TBL] [Abstract][Full Text] [Related]
19. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.
Chen CI; Cao Y; Trudel S; Reece DE; Kukreti V; Tiedemann R; Prica A; Paul H; Le LW; Levina O; Kakar S; Lau A; Chen H; Chen E
Leuk Lymphoma; 2020 Aug; 61(8):1860-1868. PubMed ID: 32476520
[TBL] [Abstract][Full Text] [Related]
20. A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.
Jhaveri KD; Flombaum C; Shah M; Latcha S
J Oncol Pharm Pract; 2012 Mar; 18(1):140-7. PubMed ID: 22392964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
